Neoprobe raises money for Lymphoseek development:
This article was originally published in Clinica
Executive Summary
Dublin, Ohio-based Neoprobe is to inject a further $8.1m, raised from its latest round of financing, into late-stage clinical development of its radiopharmaceutical agent Lymphoseek. The product will be used for assessing the spread of breast cancer and melanoma to the lymphatic system. The funds will also be used to prepare for initial clinical studies of the investigational RIGScan CR gamma detection system and to complete the commercial launch of two blood flow measurement products, the Quantix/OR and the Quantix/ND, which is expected to take place in 2005.